GoodCap Pharmaceuticals Inc.

Goodcap is developing psychedelic therapeutics for mood disorders, starting with post-traumatic stress disorder (PTSD). Their lead drug candidate combines psilocybin, a 5HT2a receptor agonist, and eugenol, a transient receptor potential (TRP) agonist, to mediate both chronic inflammation and oxidative stress, the root causes of the symptomatology of PTSD. It provides PTSD patients with immediate relief with little risk of side effects.